MindRank Announces $52 Million Series B Financing
HANGZHOU, China, July 09, 2026 (GLOBE NEWSWIRE) -- MindRank AI Ltd. (“MindRank”),…
Outliyr’s Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
Outliyr's free public database catalogs more than seventy red light therapy panels…
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM),…
Range Impact Announces Vin Ferrara, MD, MBA, Has Joined the Company as Vice President, Real Estate
CLEVELAND, OHIO, July 08, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC:…
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional…
TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan
July 07, 2026 19:00 ET | Source: TaiMed Biologics TAIPEI, July 07,…
Resmed Announces Agreement to Sell MatrixCare Business
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX:…
Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026
Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle…
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective…
